STOCK TITAN
  1. Home
  2. Sec-filings
  3. REGN
  4. [Form 4] REGENERON PHARMACEUTICALS, INC. Insider Trading Activity

Regeneron Pharmaceuticals (REGN) Insider Reports New Equity Awards

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Regeneron Pharmaceuticals’ VP Controller reported new equity awards and related share movements. On December 5, 2025, the officer received 2,064 shares of common stock at $0.0 per share as restricted stock under the Second Amended and Restated 2014 Long-Term Incentive Plan, vesting 50% on December 5, 2027 and 50% on December 5, 2029. The same day, the officer was granted a non-qualified stock option for 2,261 shares of common stock with an exercise price of $726.71 per share, expiring on December 5, 2035 and vesting in four equal annual installments beginning one year after the grant date.

On December 8, 2025, the filing shows a disposition of 989 shares of common stock at $712.94 per share. Following these transactions, the officer directly owns 5,308 common shares, with additional indirect holdings of 31 shares through a 401(k) plan and 179 shares held by a spouse, along with the 2,261 stock options.

Positive

  • None.

Negative

  • None.
Insider Pitofsky Jason
Role VP Controller
Type Security Shares Price Value
Tax Withholding Common Stock 989 $712.94 $705K
Grant/Award Non-Qualified Stock Option (right to buy) 2,261 $0.00 --
Grant/Award Common Stock 2,064 $0.00 --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 5,308 shares (Direct); Non-Qualified Stock Option (right to buy) — 2,261 shares (Direct); Common Stock — 31 shares (Indirect, By 401(k) Plan)
Footnotes (1)
  1. Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 5, 2027 and 50% on December 5, 2029. The stock option award vests in four equal annual installments, commencing one year after the date of grant.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pitofsky Jason
(Last) (First) (Middle)
777 OLD SAW MILL RIVER ROAD
(Street)
TARRYTOWN NY 10591
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
VP Controller
3. Date of Earliest Transaction (Month/Day/Year)
12/05/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/05/2025 A(1) 2,064 A $0.0 6,297 D
Common Stock 12/08/2025 F 989 D $712.94 5,308 D
Common Stock 31 I By 401(k) Plan
Common Stock 179 I by Spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right to buy) $726.71 12/05/2025 A 2,261 (2) 12/05/2035 Common Stock 2,261 $0.0 2,261 D
Explanation of Responses:
1. Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 5, 2027 and 50% on December 5, 2029.
2. The stock option award vests in four equal annual installments, commencing one year after the date of grant.
/s/ Jason Pitofsky 12/09/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did Regeneron Pharmaceuticals (REGN) disclose in this filing?

The filing shows that Regeneron Pharmaceuticals’ VP Controller received 2,064 restricted shares of common stock and a non-qualified stock option for 2,261 shares, and also reported a disposition of 989 shares of common stock.

How many restricted Regeneron (REGN) shares were granted to the VP Controller and when do they vest?

The VP Controller was granted 2,064 restricted shares of Regeneron common stock. These shares vest 50% on December 5, 2027 and 50% on December 5, 2029 under the company’s long-term incentive plan.

What are the terms of the new stock option grant reported by Regeneron (REGN)?

The officer received a non-qualified stock option to buy 2,261 shares of Regeneron common stock at an exercise price of $726.71 per share. The option expires on December 5, 2035 and vests in four equal annual installments starting one year after the grant date.

What stock sale or disposition was reported in this Regeneron (REGN) insider filing?

The filing reports a December 8, 2025 disposition of 989 shares of Regeneron common stock at a price of $712.94 per share under transaction code F.

How many Regeneron (REGN) shares does the VP Controller own after the reported transactions?

After the reported transactions, the VP Controller directly owns 5,308 shares of Regeneron common stock, plus 31 shares held through a 401(k) plan and 179 shares held by a spouse, along with 2,261 stock options.

Which compensation plan governs the restricted stock granted to the Regeneron (REGN) officer?

The 2,064 restricted shares were awarded under Regeneron’s Second Amended and Restated 2014 Long-Term Incentive Plan, as stated in the filing’s explanation of responses.